Alaunos Therapeutics, Inc.

Good day and thank you for standing by. Welcome to the Alanos Therapeutics first quarter 2023 conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your speaker today, Alex Lobo. Please go ahead.

Good morning.

Earlier this morning, ALANOS issued a press release announcing financial results for the three months ended March 31st, 2023. We encourage everyone to read today's press release, as well as the ALANOS quarterly report on Form 10-Q for the quarter ended March 31st, 2023, which was filed this morning with the SEC. The company's press release and quarterly report will also be available on the Alanos website at alanos.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 10th, 2023. Actual results could differ materially from those stated or implied by forward-looking statements made today due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law. With me today are Kevin Boyle Sr., Chief Executive Officer, Drew Dennegar, Vice President of Research and Development, and Mike Wong, Vice President of Finance. Abhi Sivastava, Vice President of Technical Operations, will also be available for the Q&A session. With that said, I would like to turn the call over to Kevin. Kevin, you may go ahead.